期刊文献+

Egyptian male breast carcinoma:patients' hormonal profile,management and outcome

埃及男性乳腺癌:患者的激素概况、治疗及疗效(英文)
下载PDF
导出
摘要 Objective:Male breast cancer(MBC) represents < 1% of all breast cancers.Hormone receptors and Her-2/neu status are established prognostic factors in female breast cancer but not yet studied enough in male breast cancer.The aim of the study was to verify the clinico-pathologic profile of male patients with breast cancer including analysis of hormone receptors and Her-2/neu state and its impact on survival rate.Methods:This is a retrospective study carried on a total of 123 male patients presented to the National Cancer Institute(NCI),Cairo University,Egypt-with breast carcinoma from January 1999 to December 2009.Results:The patients had a median age of 58(ranged from 29-92) years.About 39.8% of the patients presented with T4 lesion.At presentation,12.2% of the cases had metastasis with bone represented 86.7% of metastatic sites.About 92.7% of patients were subjected to modified radical mastectomy and radical mastectomy.Invasive duct carcinoma reported in 91.1%,and 76.4% of the patients had grade II pathology.Hormone profile was reported in 74% of the patients with 71.4% positive ER and 69.2% positive PR.Among 57 cases tested for Her-2/neu,10.5% were positive.Luminal A was the most common subtype detected in male breast carcinoma patients constituting 66.7%.Comparison with female patients with breast carcinoma revealed some differences regarding stage,hormone profile,Her-2/neu status and breast cancer subtypes.Chemotherapy as adjuvant,neo-adjuvant and metastatic was given for 73.1%,17.3% and 9.6% of the cases,with 83% of them had an anthracyclin-containing regimen.Sixty-nine patients received radiation treatment,65.2% and 34.8% of them with adjuvant and palliative aim,respectively.Dose of adjuvant radiotherapy had a median value of 4410(3400-5000) cGy.Adjuvant hormonal treatment(Tamoxafin) was given for 47 patients all of them with ER and/or PR positive for a median period of 33.5(4-60) months.The 5-year overall survival(OS),loco-regional control(LRC),metastasis-free survival(MFS) rates were 63%,68%,and 62%,respectively.Axillary lymph node metastasis and advanced tumor stage significantly worsen all survival rates.While,higher grade was associated with a poor overall survival,this was not reflected on LRC and MFS rates.Adjuvant radiotherapy and chemotherapy had significantly improved all survival rates.Conclusion:Some gender differences were detected regarding stage,hormone profile,Her-2 state,and tumor subtypes.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第2期89-98,共10页 中德临床肿瘤学杂志(英文版)
关键词 male breast carcinoma(MBC) hormonal profile OUTCOME 个人主页 乳腺癌 男性 癌病 埃及 荷尔蒙 激素受体 管理
  • 相关文献

参考文献31

  • 1Korde LA,Zujewski JA,Kamin L,et al.Multidisciplinary meeting on male breast cancer:summary and research recommendations.J Clin Oncol,2010,28:2114-2122.
  • 2Giordano SH,Cohen DS,Buzdar AU,et al.Breast carcinoma in men:a population-based study.Cancer,2004,101:51-57.
  • 3Mokhtar N,Gouda I,Adel I.Breast cancer.In:Cancer pathology registry 2003-2004 and time trend analysis.El Sheraa,2007,41.
  • 4Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial.J Clin Oncol,2009,27:1168-1176.
  • 5Edge SB,Byrd JC,Compton CC,et al.AJCC cancer staging manual.7th edition.New York:Springer.2009.
  • 6Ellis IO,Schnitt SJ,Sastre-Garau X,et al.Invasive breast carcinoma.In:World Health Organization Classification of tumors.Pathology and genetics.Tumors of the breast and female genital organs.Tavassoli FA,Devilee P,eds.Lyon:International Agency for Research on Cancer,2003.18-19.
  • 7Miller K.Immunohistochemical techniques.In:Theory and practice of histological techniques.Bancroft JD,Gamble M (eds).5th edition.Churchill Livingstone,2002.421.
  • 8Heinrich JK,B(o)ttcher-Luiz F,Andrade LL,et al.HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization.Int J Gynecol Cancer,2004,14:1078-1085.
  • 9Nahleh Z,Girnius S.Male breast cancer:a gender issue.Nat Clin Pract Oncol,2006,3:428-437.
  • 10Anderson WF,Althuis MD,Brinton LA,et al.Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat,2004,83:77-86.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部